Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Rating of “Moderate Buy” by Brokerages

Senti Biosciences, Inc. (NASDAQ:SNTI) has earned an average rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $9.00.

Several equities analysts have commented on the stock. HC Wainwright initiated coverage on shares of Senti Biosciences in a report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 price objective on the stock. Chardan Capital lifted their target price on shares of Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Leerink Partners began coverage on shares of Senti Biosciences in a research note on Friday, November 21st. They issued an “outperform” rating and a $6.00 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Senti Biosciences to a “sell” rating in a report on Saturday, December 13th.

Senti Biosciences Stock Up 3.8%

NASDAQ:SNTI opened at $1.10 on Friday. Senti Biosciences has a 12-month low of $1.04 and a 12-month high of $5.10. The firm has a market capitalization of $28.92 million, a price-to-earnings ratio of -0.33 and a beta of 2.13. The stock’s 50 day moving average price is $1.54 and its two-hundred day moving average price is $1.68.

Senti Biosciences (NASDAQ:SNTI) last issued its earnings results on Thursday, November 13th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.10). Equities research analysts expect that Senti Biosciences will post -14.54 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares in the last quarter. Armistice Capital LLC acquired a new position in shares of Senti Biosciences in the second quarter valued at about $1,883,000. Finally, Citadel Advisors LLC acquired a new position in shares of Senti Biosciences in the third quarter valued at about $117,000. 25.70% of the stock is owned by institutional investors and hedge funds.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.